NYSE:EWMedical Equipment
Edwards Lifesciences (EW) Valuation Check After FDA Nod For SAPIEN M3 And 2026 Growth Outlook
Edwards Lifesciences (EW) is back in focus after the U.S. FDA cleared its SAPIEN M3 transcatheter mitral valve replacement system and the company issued 2026 sales guidance tied to product momentum and innovation.
See our latest analysis for Edwards Lifesciences.
The FDA approval of SAPIEN M3 and Edwards Lifesciences' 2026 sales outlook arrive as the share price trades at US$87.18, with a 7-day share price return of 5.75% and a 1-year total shareholder return of 22.12%. This suggests momentum...